Global Market Direct’s pharmaceuticals report, “ConjuGon, Inc. - Product Pipeline Review - 2013” provides data on the ConjuGon, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ConjuGon, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ConjuGon, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- ConjuGon, Inc. - Brief ConjuGon, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of ConjuGon, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of ConjuGon, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the ConjuGon, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate ConjuGon, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of ConjuGon, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the ConjuGon, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with ConjuGon, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of ConjuGon, Inc. and identify potential opportunities in those areas.
Table Of Contents
ConjuGon, Inc. - Product Pipeline Review - 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 ConjuGon, Inc. Snapshot 4 ConjuGon, Inc. Overview 4 Key Information 4 Key Facts 4 ConjuGon, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 ConjuGon, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 ConjuGon, Inc. - Pipeline Products Glance 9 ConjuGon, Inc. Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 ConjuGon, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Discovery Products/Combination Treatment Modalities 11 ConjuGon, Inc. - Drug Profiles 12 B-4474 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 C-1205 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Drug For Gram Positive Wound Infections 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 ConjuGon, Inc. - Pipeline Analysis 15 ConjuGon, Inc. - Pipeline Products by Therapeutic Class 15 ConjuGon, Inc. - Locations And Subsidiaries 16 Head Office 16 Appendix 17 Methodology 17 Coverage 17 Secondary Research 17 Primary Research 17 Expert Panel Validation 17 Contact Us 18 Disclaimer 18
List of Tables
ConjuGon, Inc., Key Information 4 ConjuGon, Inc., Key Facts 4 ConjuGon, Inc. - Pipeline by Indication, 2013 6 ConjuGon, Inc. - Pipeline by Stage of Development, 2013 7 ConjuGon, Inc. - Monotherapy Products in Pipeline, 2013 8 ConjuGon, Inc. - Phase I, 2013 9 ConjuGon, Inc. - Preclinical, 2013 10 ConjuGon, Inc. - Discovery, 2013 11 ConjuGon, Inc. - Pipeline By Therapeutic Class, 2013 15
List of Figures
ConjuGon, Inc. - Pipeline by Indication, 2013 6 ConjuGon, Inc. - Pipeline by Stage of Development, 2013 7 ConjuGon, Inc. - Monotherapy Products in Pipeline, 2013 8 ConjuGon, Inc. - Pipeline By Therapeutic Class, 2013 15